Conor P Kerley1,2, Katrina Hutchinson3,4, Jessica Bramham5, Aisling McGowan1, John Faul1, Liam Cormican1. 1. Respiratory and Sleep Diagnostics Department, Connolly Hospital, Blanchardstown, Dublin, Ireland. 2. School of Medicine and Medical Sciences, University College Dublin, Belfield, Dublin, Ireland. 3. Biomnis Ireland, Sandyford Business Estate, Dublin, Ireland. 4. NCBES, NUI Galway, Ireland. 5. School of Psychology, University College, Dublin, Belfield, Dublin, Ireland.
Abstract
STUDY OBJECTIVES: Our group and others have reported a high rate of vitamin D deficiency in obstructive sleep apnea (OSA), where vitamin D levels (25(OH) D) correlate negatively with OSA severity and some of its associated metabolic alterations. Data regarding vitamin D supplementation in OSA are lacking. We wanted to evaluate the effect of vitamin D3 supplementation on OSA symptoms and metabolic parameters. METHODS: We conducted a pilot, double-blind, randomized, placebo-controlled trial of daily supplementation with 4,000 IU vitamin D3 (D3) or placebo (PL). We studied 19 Caucasian adults (14 male, mean age 55 y, mean body mass index [BMI] 30.4 kg/m2) with OSA. Fifteen patients were stable on continuous positive airways pressure (CPAP) therapy, whereas four were CPAP naïve. Assessments were completed at baseline and after 15 weeks of supplementation. Outcomes included sleepiness (Epworth Sleepiness Scale), quality of life (Sleep Apnea Quality of Life Inventory), fatigue (fatigue severity scale) and neuropsychological function (trail making test and Connor's Continuous Performance Test II). In addition, we assessed biochemical indices of vitamin D status (25(OH)D, calcium), inflammation (high sensitivity C-reactive protein, and lipoprotein-associated phospholipase A2), lipids (total cholesterol [low-density and high-density lipoprotein]) and glycemic indices (fasting glucose, oral glucose tolerance test). RESULTS: There was no change in BMI, medication, or CPAP usage. Although there was no change in neuropsychological or quality of life indices, we observed a significant increase in 25(OH)D (p = 0.00001) and significant decreases in both low-density lipoprotein (p = 0.04) and lipoprotein-associated phospholipase A2 (p = 0.037) as well as trends toward decreased fasting glucose (p = 0.09) and increased high-density lipoprotein (p = 0.07) in the D3 group compared to PL. CONCLUSIONS:Vitamin D3 supplementation increased vitamin D levels and decreased metabolic markers compared to placebo. Larger trials are required.
RCT Entities:
STUDY OBJECTIVES: Our group and others have reported a high rate of vitamin Ddeficiency in obstructive sleep apnea (OSA), where vitamin D levels (25(OH) D) correlate negatively with OSA severity and some of its associated metabolic alterations. Data regarding vitamin D supplementation in OSA are lacking. We wanted to evaluate the effect of vitamin D3 supplementation on OSA symptoms and metabolic parameters. METHODS: We conducted a pilot, double-blind, randomized, placebo-controlled trial of daily supplementation with 4,000 IU vitamin D3 (D3) or placebo (PL). We studied 19 Caucasian adults (14 male, mean age 55 y, mean body mass index [BMI] 30.4 kg/m2) with OSA. Fifteen patients were stable on continuous positive airways pressure (CPAP) therapy, whereas four were CPAP naïve. Assessments were completed at baseline and after 15 weeks of supplementation. Outcomes included sleepiness (Epworth Sleepiness Scale), quality of life (Sleep Apnea Quality of Life Inventory), fatigue (fatigue severity scale) and neuropsychological function (trail making test and Connor's Continuous Performance Test II). In addition, we assessed biochemical indices of vitamin D status (25(OH)D, calcium), inflammation (high sensitivity C-reactive protein, and lipoprotein-associated phospholipase A2), lipids (total cholesterol [low-density and high-density lipoprotein]) and glycemic indices (fasting glucose, oral glucose tolerance test). RESULTS: There was no change in BMI, medication, or CPAP usage. Although there was no change in neuropsychological or quality of life indices, we observed a significant increase in 25(OH)D (p = 0.00001) and significant decreases in both low-density lipoprotein (p = 0.04) and lipoprotein-associated phospholipase A2 (p = 0.037) as well as trends toward decreased fasting glucose (p = 0.09) and increased high-density lipoprotein (p = 0.07) in the D3 group compared to PL. CONCLUSIONS:Vitamin D3 supplementation increased vitamin D levels and decreased metabolic markers compared to placebo. Larger trials are required.
Authors: Isaac Shpirer; Arnon Elizur; Ran Shorer; Ruth Bernstein Peretz; Jose M Rabey; Michael Khaigrekht Journal: Sleep Breath Date: 2011-09-04 Impact factor: 2.816
Authors: Antonia Barceló; Cristina Esquinas; Javier Piérola; Mónica De la Peña; Manuel Sánchez-de-la-Torre; Josep María Montserrat; José María Marín; Joaquín Duran; Meritxell Arqué; Josep Miquel Bauça; Ferrán Barbé Journal: Respiration Date: 2012-11-15 Impact factor: 3.580
Authors: T Mete; Y Yalcin; D Berker; B Ciftci; S F Guven; O Topaloglu; H C Yavuz; S Guler Journal: J Endocrinol Invest Date: 2013-04-02 Impact factor: 4.256
Authors: Umesh Goswami; Kristine E Ensrud; Misti L Paudel; Susan Redline; Eva S Schernhammer; James M Shikany; Katie L Stone; Ken M Kunisaki Journal: Ann Am Thorac Soc Date: 2016-05
Authors: Ben Schöttker; Sabine Kuznia; Dana Clarissa Laetsch; David Czock; Annette Kopp-Schneider; Reiner Caspari; Hermann Brenner Journal: BMC Cancer Date: 2020-08-08 Impact factor: 4.430